We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Soft Tissue Sarcoma
MedXY News
EnglishTag

Soft Tissue Sarcoma

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma
Hematology-OncologycabozantinibLeiomyosarcoma

Cabozantinib Plus Temozolomide: A Promising Dual-Pathway Approach for Advanced Leiomyosarcoma

By MedXY|Feb 18, 2026

A phase 2 trial demonstrates that combining cabozantinib with temozolomide provides significant progression-free survival benefits for patients with advanced leiomyosarcoma, achieving a 74% 12-week PFS rate with a manageable safety profile,

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma
newsanlotinibchemotherapy

Anlotinib Combined with Anthracycline-Ifosfamide Regimen Shows Promising Efficacy in First-line Treatment of Advanced Soft-Tissue Sarcoma

© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
By MedXY|Jan 20, 2026

This Phase II trial evaluates first-line anlotinib plus anthracyclines and ifosfamide followed by anlotinib maintenance for advanced soft-tissue sarcoma, showing an objective response rate of 30.8% and a manageable safety profile, suggestin

Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens
newshypofractionationradiation oncology

Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens

By MedXY|Dec 21, 2025

A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy
Hematology-Oncologygene therapySoft Tissue Sarcoma

Advances in Targeted and Gene Therapies: Promising Data on KRAS G12D Inhibitors, DR5 Agonists, and Ocular Gene Therapy

By MedXY|Oct 24, 2025

Recent clinical trials report encouraging tumor shrinkage with KRAS G12D inhibitor VS-7375, significant progression-free survival benefit in soft tissue sarcoma with ozekibart, and a novel gene therapy acquisition targeting wet AMD.

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial
newsDoxorubicinmaintenance therapy

Regorafenib as Maintenance Therapy in Advanced Non-Adipocytic Soft Tissue Sarcomas: Positive Impact on Progression-Free Survival in a Randomised Trial

By MedXY|Oct 2, 2025

The EREMISS trial demonstrates that regorafenib significantly prolongs progression-free survival as maintenance therapy after first-line doxorubicin chemotherapy in advanced non-adipocytic soft tissue sarcoma patients, with manageable safet

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities